This study utilized an analytical framework and parameters similar to those used in previous research that assessed pemigatinib cost-effectiveness in patients with advanced ICC and FGFR2 fusion [27, 28]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.